Company intelligence / Profile preview
Reforgene Medicine
Guangzhou, Guangdong, China
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
01
Overview
The company’s lead program, RM‑001, a gene-editing cell therapy for transfusion-dependent β-thalassemia, achieved a reported “100% cure rate” in a Phase I trial. Additional pipeline assets include early-stage therapies targeting alpha-thalassemia and Usher syndrome type II using gene editing and stem cell approaches. Other preclinical candidates address genetic disorders in ophthalmology, neurology, and oncology.[2][8][10]
Clinical results beyond RM‑001 have not been publicly detailed.
Pipeline breadth estimates range from at least three named programs with additional undisclosed assets under development.
[Note on “100% cure rate”: This refers to interim data from an early-phase trial; full peer-reviewed publication not available.]
[Note on pipeline breadth/summary based on available public disclosures as of June 2025.]
- Therapeutic areas
- Rare DiseasesHematology
- Modalities
- Gene therapyGene editingHematopoietic stem cell therapyAAV based gene therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Reforgene Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reforgene Medicine.